Simplifying Global Compliance
Eli Lilly Submitting sNDA for Cymbalta to Treat Fibromyalgia
Washington Drug Letter
Eli Lilly has submitted a supplemental new drug application (sNDA) to the FDA for its antidepressant Cymbalta to manage fibromyalgia, the company announced.
To View This Article:
Buy This Article Now
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing